Compare Eli Lilly And Co (LLY) vs Yum! Brands, Inc. (YUM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Yum! Brands, Inc. — how do they compare? Eli Lilly And Co trades at $1,220 (market cap $1.08T), while Yum! Brands, Inc. trades at $150 (market cap $39.50B). The key difference: Eli Lilly And Co is far larger — about 27.3× Yum! Brands, Inc.'s market cap, and Yum! Brands, Inc. pays the higher dividend (2.07%). Which is the better fit depends on your goals.
| LLY | YUM | |
|---|---|---|
Market Cap | $1.08T | $39.50B |
Sector | Health | Consumer Cyclical |
52-Week High | $1.24K | $168.16 |
52-Week Low | $639.43 | $138.21 |
Enterprise Value | $1.13T | $51.10B |
Dividend Yield | 0.57% | 2.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,223.97, down 0.62% on the day, maintaining strong bullish momentum with consecutive earnings beats and robust revenue growth. The stock shows technical strength above key support levels at $1,207, while fundamentals reveal exceptional profitability with 33.53% net margins and 102.44% ROE. Recent quarterly results exceeded expectations, with Q2 2026 revenue surging 48% to $23 billion driven by Mounjaro and Zepbound demand.
Outlook remains positive with analyst consensus targeting $1,380 and 73% buy ratings, though elevated valuations (P/E 40.8) and regulatory risks around weight-loss drug competition present headwinds. The company's pipeline advancement with retatrutide filing expected in 2027 provides medium-term growth catalysts, but investors should monitor execution risks in the competitive obesity drug market.
YUM trades at $150.15, up 3.32% in the past 24 hours, with a bearish technical signal from moving averages but neutral oscillators. Recent earnings show a Q2 2026 beat with EPS of $1.62 versus $1.57 expected, while revenue grew to $8.21B in 2025. The company completed the sale of Pizza Hut China for $1.2B in August 2026, aiming to streamline operations and reduce debt. Cash flow from operations improved to $2.01B in 2025, supporting a dividend payment of $0.75 per share.
The outlook is mixed, with analyst consensus leaning hold (56.87%) but a price target of $174.60 implying 16% upside. Risks include ongoing legal investigations and a parasite outbreak impacting Taco Bell sales, though management reports recovery. Debt remains high at $11.25B long-term, but the debt-to-asset ratio improved to 143.49 in 2025. Execution on digital growth and brand focus post-Pizza Hut sale are key to unlocking value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Yum! Brands, Inc.
Yum Brands is a U.S.-based restaurant operator featuring a portfolio of four brands: KFC (26,930 global units), Pizza Hut (18,380 units), Taco Bell (7,790 units), and The Habit Burger (310 units) at year-end 2021. With $58 billion in 2021 systemwide sales, the firm is the second-largest restaurant company in the world, behind McDonald's ($112.5 billion) but ahead of Restaurant Brands International ($36 billion) and Starbucks ($25 billion). Yum is 98% franchised, with the largest franchisee, Yum China, created via a 2016 spinoff transaction (after which Yum China agreed to pay 3% royalties to Yum Brands in perpetuity). Yum is the newest evolution of Tricon Brands, formerly a division of PepsiCo, and generates the bulk of its revenue from franchise royalties and marketing contributions.
Read more on YUM →
